Journal
SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/srep23613
Keywords
-
Categories
Funding
- National Cancer Center Research and Development Fund [26-A-14, 26-A-12]
- Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour, and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology
- Princess Takamatsu Cancer Research Fund
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and development, AMED [15ck0106114 h0002]
- Grants-in-Aid for Scientific Research [15H04316] Funding Source: KAKEN
Ask authors/readers for more resources
The diagnosis of early and aggressive types of cancer is important for providing effective cancer therapy. Cancer-induced fibrin clots exist only within lesions. Previously, we developed a monoclonal antibody (clone 102-10) that recognizes insoluble fibrin but not fibrinogen or soluble fibrin and confirmed that fibrin clots form continuously in various cancers. Here, we describe the development of a Fab fragment probe of clone 102-10 for tumour imaging. The distribution of 102-10 Fab was investigated in genetically engineered mice bearing pancreatic ductal adenocarcinoma (PDAC), and its effect on blood coagulation was examined. Immunohistochemical and ex vivo imaging revealed that 102-10 Fab was distributed selectively in fibrin clots in PDAC tumours 3 h after injection and that it disappeared from the body after 24 h. 102-10 Fab had no influence on blood coagulation or fibrinolysis. Tumour imaging using anti-fibrin Fab may provide a safe and effective method for the diagnosis of invasive cancers by detecting fibrin clots in tumour stroma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available